Medical Marijuana: Frequently Asked Questions

Medical marijuana sits at the intersection of active federal-state legal tension, evolving clinical evidence, and deeply personal health decisions — which makes it one of the more genuinely complicated topics a patient can walk into unprepared. These questions cover the regulatory mechanics, the clinical framework, the classification system, and the misconceptions that reliably cause problems for patients who encounter them too late.

What triggers a formal review or action?

The short answer: crossing a jurisdictional line, either legal or clinical, usually sets things in motion. On the regulatory side, the Drug Enforcement Administration (DEA) still classifies cannabis as a Schedule I controlled substance under the Controlled Substances Act — meaning federal enforcement authority exists even in states with robust medical programs. Dispensaries operating under state licenses have faced federal asset forfeiture proceedings in past enforcement cycles, and patients who travel across state lines with state-issued medical cannabis can face federal possession charges regardless of their medical status.

On the clinical side, a physician's recommendation can be reviewed or revoked if a patient's condition changes, if documentation lapses, or if a state medical board investigates the recommending physician's practices. Some states conduct audits of certifying practitioners: Oregon, for instance, has historically scrutinized physicians who certify patients at unusually high rates.

How do qualified professionals approach this?

Physicians who work within medical marijuana programs operate under state-specific frameworks, not a unified federal standard. The recommending physician's role is to evaluate whether a patient meets a state's list of qualifying conditions for medical marijuana, document that determination, and issue a written certification — not a prescription, because federal law prohibits prescribing a Schedule I substance.

Qualified practitioners typically conduct a full medical history review, confirm diagnosis with supporting records, assess whether conventional treatments have been attempted, and document their clinical rationale. The American Academy of Neurology and the American College of Physicians have both published position statements acknowledging therapeutic evidence for specific conditions — notably epilepsy and chronic pain — while calling for expanded research infrastructure.

What should someone know before engaging?

The Medical Marijuana Authority homepage outlines the broad landscape, but three structural realities deserve upfront attention. First, medical marijuana programs are state-administered, meaning eligibility, card costs, renewal timelines, and qualifying conditions differ across all 38 states (plus Washington D.C.) that had operational medical programs as of 2023 (NCSL State Medical Marijuana Laws). Second, no health insurer — including Medicare and Medicaid — covers medical marijuana costs because federal Schedule I status blocks coverage. Third, employer drug testing policies operate independently of state patient protections in most states; a valid medical card does not guarantee protection from workplace consequences.

What does this actually cover?

Medical marijuana refers to the use of the cannabis plant, or its isolated cannabinoids, under physician supervision to address a diagnosed medical condition. The two primary active compounds are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) — both are explained in detail at Cannabinoids: THC and CBD Explained. These compounds interact with the body's endocannabinoid system, which modulates pain signaling, immune response, mood, and appetite.

Clinically recognized applications span a documented range: chronic pain, chemotherapy-induced nausea, muscle spasticity in multiple sclerosis, treatment-resistant epilepsy, glaucoma-related intraocular pressure, and appetite stimulation in HIV/AIDS wasting syndrome. The FDA has approved 3 cannabis-derived or cannabis-related medications — Epidiolex (cannabidiol), Marinol (dronabinol), and Syndros (dronabinol) — which are detailed at FDA-Approved Cannabis-Based Medications.

What are the most common issues encountered?

Documentation failures account for a significant share of program complications. Patients who cannot produce physician records confirming their qualifying diagnosis frequently face certification delays or denials. Renewal lapses — missing the state-mandated renewal window, which ranges from 1 to 3 years depending on the state — result in card expiration and a loss of legal protection during the gap.

Product-related issues also surface regularly. Without standardized federal labeling requirements, cannabinoid potency on dispensary products can vary from labeled concentrations, a finding documented in a 2015 JAMA Internal Medicine study that found 23 of 75 tested products were mislabeled for CBD content. Patients unfamiliar with medical marijuana delivery methods sometimes experience unintended effects when switching between inhalation and oral forms, which have dramatically different onset and duration profiles.

How does classification work in practice?

State programs use two parallel classification systems: condition-based eligibility and product-type categorization. Condition classification determines access — a patient must have a documented qualifying condition. Product classification governs what can be purchased. Most state dispensaries organize inventory by cannabinoid ratio (THC-dominant, CBD-dominant, balanced), by strain type (indica, sativa, hybrid — though these terms are increasingly considered imprecise by botanists), and by delivery format (flower, concentrate, tincture, edible, topical).

The federal-versus-state legal conflict creates a classification anomaly: a product that is fully legal to possess under state law simultaneously constitutes a federal controlled substance. This dual classification status affects banking access for dispensaries, research funding availability, and interstate commerce.

What is typically involved in the process?

The pathway from patient to cardholder follows a structured sequence in every state program:

1. Establish a qualifying diagnosis — confirmed by medical records, imaging, lab results, or specialist documentation.
2. Consult a certifying physician — either a primary care provider registered with the state program or a specialist in finding a medical marijuana doctor.
3. Receive a written certification — the physician's formal documentation of the qualifying condition and recommendation.
4. Submit a state registry application — including the physician certification, a government-issued ID, proof of state residency, and the applicable fee (which ranges from $0 in fee-waiver states to $200 in states with higher administrative costs).
5. Receive the medical marijuana card — issued by the state health department, valid for the program's defined term.
6. Renew before expiration — following the medical marijuana card renewal process specific to the issuing state.

What are the most common misconceptions?

The most durable misconception is that a medical marijuana card functions like a prescription — that it authorizes a specific product at a specific dose. It does not. The certification confirms eligibility; what a patient actually purchases is largely self-directed within whatever product categories the dispensary stocks. Dosing is not standardized across state programs, and physicians are generally prohibited from specifying brand or product in their certifications.

A second persistent misconception holds that "medical" implies lower potency than recreational products. In states where both programs operate, the same cultivar can appear in both markets. The medical marijuana vs. recreational marijuana distinction is primarily regulatory and tax-related, not pharmacological. Medical products in some states carry lower excise taxes and may include higher-potency concentrations not available recreationally — which is the reverse of what many patients expect.

Finally, some patients assume that long-term use carries no meaningful risk profile. The research on medical marijuana and mental health risks identifies elevated concern for individuals with a personal or family history of psychosis, and heavy adolescent use is associated with measurable cognitive effects in longitudinal studies published by the National Institute on Drug Abuse (NIDA).